Summary

Point-of-Care Glucose Testing Market Growth & Trends

The global point-of-care glucose testing market size is expected to reach USD 4.1 billion by 2028 growing at a CAGR of 3.9%, according to a new report by Grand View Research, Inc. An increase in the demand for point-of-care testing (POCT) has been witnessed in recent years. As compared to the conventional laboratory testing performed central lab settings, glucose POCT aids in performing effective diagnosis at the patient’s bedside. Easy and convenient operation of POCT has largely favored the growing usage of glucose meters across medical settings.

The demand for performing bedside monitoring of blood sugar levels efficiently in a capillary blood sample and the need to ensure better management of carbohydrate metabolism has propelled the point-of-care glucose testing market players to launch innovative glucose meters in the market. Various companies are investing in the development of needle-less blood glucose monitoring devices to offer painless management of diabetes in patients.

For instance, GlucoTrack - a product manufactured by Integrity Applications (Israel) performs quantification using electromagnetic, ultrasonic, and thermal waves in combination. In addition, Eversense is another painless glucose monitoring subcutaneous implant offered by Senseonics. This implant is able to quantify glucose levels in interstitial fluid when placed beneath the skin. This is followed by data transmission to show the results in real time.

The latest no-code monitoring systems help in minimizing the errors that occur due to incorrect entry of strip codes. Whereas, others are incorporating noble metals such as silver, gold, and platinum which effectively reduces the electrical noise further improving accuracy.

Point-of-Care Glucose Testing Market Report Highlights

• Accu-Chek Inform II accounted for the largest revenue share in 2018 and is anticipated to maintain this trend throughout the forecast period

• Bayer CONTOUR blood glucose monitoring system is set to grow with a CAGR of 5.5% from 2019-2025

• In terms of volume, the i-STAT ranked above all owing to its multipurpose utility in the diagnostics industry

• North America is the leading regional market due to the higher penetration of novel diagnostic techniques

• Asia Pacific has registered the fastest growth rate owing to numerous untapped growth opportunities in diagnostics and ever-increasing prevalence of diabetes

• A robust network of local manufacturers has significantly contributed to the revenue generated in this region Some of the key market participants are F. Hoffmann-La Roche Ltd., Abbott, LifeScan, Inc., and Nova Biomedical among others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.3.5.1 Data for primary interviews in North America
1.3.5.3 Data for Primary Interviews in Europe
1.3.5.4 Data for Primary Interviews in APAC
1.3.5.6 Data for Primary Interviews in Latin America
1.3.5.8 Data for Primary Interviews in MEA
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective 1:
1.8.2 Objective 2:
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Market Variables, Trends & Scope
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Introduction of CLIA waived tests
3.1.1.2 Growing prevalence of diabetes
3.1.1.3 Rising demand for short turnaround time glucose POC testing
3.1.2 Market Restraint Analysis
3.1.2.1 Potential interference and calibration issues in glucose meters
3.1.2.2 Presence of ambiguous regulatory as well as reimbursement framework
3.2 Point-of-Care (POC) Glucose Testing Market Analysis Tools
3.2.1 Industry Analysis - Porter’s
3.2.2 PESTEL Analysis
3.3 Point-of-Care (POC) Glucose Testing Market: Covid-19 Impact Analysis
Chapter 4 Point-of-Care (POC) Glucose Testing: Product Estimates & Trend Analysis
4.1 Definitions and Scope
4.2 Product Market Share Analysis
4.3 Segment Dashboard
4.4 Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
4.5 Accu-Check Aviva Meter
4.5.1 Accu-Check Aviva Meter market estimates and forecast, 2016 - 2028
4.6 Onetouch Verio Flex
4.6.1 Onetouch Verio Flex market estimates and forecast, 2016 - 2028
4.7 i-STAT
4.7.1 I-STAT market estimates and forecast, 2016 - 2028
4.8 Freestyle Lite
4.8.1 Freestyle Lite market estimates and forecast, 2016 - 2028
4.9 Bayer CONTOUR Blood Glucose Monitoring System
4.9.1 BAYER CONTOUR Blood Glucose Monitoring System market estimates and forecast, 2016 - 2028
4.10 True Metrix
4.10.1 TRUE METRIX market estimates and forecast, 2016 - 2028
4.11 Accu-Check Inform II
4.11.1 Accu-Check Inform II market estimates and forecast, 2016 - 2028
4.12 StatStrip
4.12.1 StatStrip market estimates and forecast, 2016 - 2028
Chapter 5 Point-of-care (POC) Glucose Testing Market: Regional Market Analysis, 2016-2028 (Value) (USD Million)
5.1 Market share analysis, 2020 & 2028
5.2 Regional Market Dashboard
5.3 North America
5.3.1 Market, 2016 - 2028 (USD Million)
5.3.2 U.S.
5.3.2.1 Market, 2016 - 2028 (USD Million)
5.3.3 Canada
5.3.3.1 Market, 2016 - 2028 (USD Million)
5.4 Europe
5.4.1 Market, 2016 - 2028 (USD Million)
5.4.2 U.K.
5.4.2.1 Market, 2016 - 2028 (USD Million)
5.4.3 Germany
5.4.3.1 Market, 2016 - 2028 (USD Million)
5.4.4 France
5.4.4.1 Market, 2016 - 2028 (USD Million)
5.4.5 Italy
5.4.5.1 Market, 2016 - 2028 (USD Million)
5.4.6 Spain
5.4.6.1 Market, 2016 - 2028 (USD Million)
5.4.7 Russia
5.4.7.1 Market, 2016 - 2028 (USD Million)
5.5 Asia Pacific
5.5.1 Market, 2016 - 2028 (USD Million)
5.5.2 Japan
5.5.2.1 Market, 2016 - 2028 (USD Million)
5.5.3 China
5.5.3.1 Market, 2016 - 2028 (USD Million)
5.5.4 India
5.5.4.1 Market, 2016 - 2028 (USD Million)
5.5.5 Australia
5.5.5.1 Market, 2016 - 2028 (USD Million)
5.5.6 South Korea
5.5.6.1 Market, 2016 - 2028 (USD Million)
5.5.7 Thailand
5.5.7.1 Market, 2016 - 2028 (USD Million)
5.6 Latin America
5.6.1 Market, 2016 - 2028 (USD Million)
5.6.2 Brazil
5.6.2.1 Market, 2016 - 2028 (USD Million)
5.6.3 Mexico
5.6.3.1 Market, 2016 - 2028 (USD Million)
5.6.4 Argentina
5.6.4.1 Market, 2016 - 2028 (USD Million)
5.6.5 Colombia
5.6.5.1 Market, 2016 - 2028 (USD Million)
5.7 Middle East and Africa
5.7.1 Market, 2016 - 2028 (USD Million)
5.7.2 South Africa
5.7.2.1 Market, 2016 - 2028 (USD Million)
5.7.3 Saudi Arabia
5.7.3.1 Market, 2016 - 2028 (USD Million)
5.7.4 UAE
5.7.4.1 Market, 2016 - 2028 (USD Million)
Chapter 6 Competitive Landscape
6.1 Company profiles
6.1.1 F. Hoffmann-La Roche Ltd.
6.1.1.1 Company Overview
6.1.1.2 Financial performance
6.1.1.3 Product Benchmarking
6.1.1.4 recent developments
6.1.2 Abbott
6.1.2.1 Company Overview
6.1.2.2 Financial performance
6.1.2.3 Product Benchmarking
6.1.2.4 Recent Developments
6.1.3 Nipro
6.1.3.1 Company Overview
6.1.3.2 Financial Performance
6.1.3.3 Product Benchmarking
6.1.4 PlatInium Equity Advisors, LLC (Lifescan, Inc.)
6.1.4.1 Company Overview
6.1.4.2 Product Benchmarking
6.1.4.3 Recent Developments
6.1.5 Nova Biomedical
6.1.5.1 Company Overview
6.1.5.2 Product Benchmarking
6.1.5.3 Recent Developments
6.1.6 ACON Laboratories
6.1.6.1 Company Overview
6.1.6.2 Product Benchmarking
6.1.6.3 Recent Developments
6.1.7 Trividia Health, Inc.
6.1.7.1 Company Overview
6.1.7.2 Product Benchmarking
6.1.7.3 Recent Developments
6.1.8 Prodigy Diabetes Care, LLC
6.1.8.1 Company Overview
6.1.8.2 Product Benchmarking
6.1.9 Bayer AG/Ascensia Diabetes Care Holdings AG
6.1.9.1 Company Overview
6.1.9.2 Financial Performance
6.1.9.3 Product Benchmarking
6.1.10 EKF Diagnostics
6.1.10.1 Company Overview
6.1.10.2 Financial Performance
6.1.10.3 Product benchmarking



List of Tables

TABLE 1 Examples: CLIA waived tests
TABLE 2 North America diabetes prevalence (National prevalence %), 2013 & 2035
TABLE 3 Europe diabetes prevalence (National prevalence %), 2013 & 2035
TABLE 4 Asia Pacific diabetes prevalence (National prevalence %), 2013 & 2035
TABLE 5 Latin America diabetes prevalence (National prevalence %), 2013 & 2035
TABLE 6 MEA and Africa diabetes prevalence (National prevalence %), 2013 & 2035
TABLE 7 CIS diabetes prevalence (National prevalence %), 2013 & 2035
TABLE 8 Specifications of Accu-Chek
TABLE 9 Specifications of Accu-Chek Guide Me meter
TABLE 10 Specifications of Accu-Chek Aviva meter
TABLE 11 Specifications of Accu-Chek Aviva meter
TABLE 12 Specifications of Accu-Chek Nanometer
TABLE 13 Specifications of OneTouch Verio Flex meter
TABLE 14 Specifications of the i-STAT analyzer
TABLE 15 Specifications of Freestyle Lite system
TABLE 16 Specifications of Bayer CONTOUR meter
TABLE 17 Specifications of TRUE METRIX
TABLE 18 Features and properties of ACCU-CHEK INFORM II
TABLE 19 Specifications of STATSTRIP
TABLE 20 STATSTRIP: Improved Sensitivity for Detecting Hypoglycemia
TABLE 21 Significant decline in deaths caused by StatStrip
TABLE 22 Glucose meter offered by One Drop
TABLE 23 HemoCue AB: Glucose POC diagnostics
TABLE 24 Dexcom glucose testing products marketed in France
TABLE 25 Some of the local glucose POC testing manufacturers in China
TABLE 26 Some of the local glucose POC testing manufacturers in India
TABLE 27 Primary guidelines for glucose POC testing in Australia
TABLE 28 Prevalence of diabetes and related risk factors; 2016
TABLE 29 Availability of basic technologies in the Brazilian primary care facilities


List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Point-of-care diagnostics: Market trends & outlook
FIG. 8 Market segmentation & scope
FIG. 9 Glucose point-of-care diagnostics/testing market: Driver relevance analysis (Current & future impact)
FIG. 10 Shift in POC molecular diagnostic trends
FIG. 11 Current and projected prevalence of diabetes, by geography, 2013 & 2035 (%)
FIG. 12 Schematic representation of POCT device connectivity
FIG. 13 Point of care diagnostics market: Restraint relevance analysis (Current & future impact)
FIG. 14 Point-of-care diagnostics: SWOT analysis, by factor (Political & legal, economic, and technological)
FIG. 15 Point-of-care diagnostics: Porter’s five forces analysis
FIG. 16 Glucose point-of-care diagnostics market product outlook key takeaways
FIG. 17 Accu Check Aviva meter market revenue, 2016 - 2028 (USD Million)
FIG. 19 Onetouch Verio Flex market revenue, 2016 - 2028 (USD Million)
FIG. 20 i-STAT market revenue, 2016 - 2028 (USD Million)
FIG. 21 Freestyle Lite market revenue, 2016 - 2028 (USD Million)
FIG. 22 Bayer CONTOUR blood glucose monitoring system market revenue, 2016 - 2028 (USD Million)
FIG. 23 True Metrix market revenue, 2016 - 2028 (USD Million)
FIG. 24 Accu-Chek Inform II market revenue, 2016 - 2028 (USD Million)
FIG. 25 StatStrip market revenue, 2016 - 2028 (USD Million)
FIG. 26 Regional market place: Key takeaways
FIG. 27 North America point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 28 U.S. point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 29 Canada point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 30 Europe point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 31 Germany point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 32 U.K. point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 33 France point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 34 Italy point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 35 Spain point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 36 Russia point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 37 Asia Pacific point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 38 Japan point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 39 China point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 40 India point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 41 Australia point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 41 South Korea point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 43 Thailand point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 44 Latin America point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 45 Brazil point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 46 Mexico point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 47 Argentina point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 48 Colombia point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 49 Middle East & Africa point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 50 South Africa point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 51 Saudi Arabia point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 52 UAE point-of-care glucose testing market revenue, 2016 - 2028 (USD Million)
FIG. 53 Strategy framework
FIG. 54 Participant categorization